Valuation: Senzime AB

Market Cap 410M 41.13M 36.17M 34.2M 31.02M 58.26M 3.95B 58.6M 158M 2.01B 154M 151M 6.47B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 410M 41.13M 36.17M 34.2M 31.02M 58.26M 3.95B 58.6M 158M 2.01B 154M 151M 6.47B EV / Sales 2026 *
3.21x
EV / Sales 2027 * 2.01x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day+7.64%
1 week-4.93%
Current month-26.72%
1 month-26.52%
3 months-37.98%
6 months-36.85%
Current year-51.76%
1 week 2.35
Extreme 2.35
2.88
1 month 2.35
Extreme 2.35
3.68
Current year 2.35
Extreme 2.35
6
1 year 2.35
Extreme 2.35
6.51
3 years 2.35
Extreme 2.35
9.6
5 years 2.35
Extreme 2.35
24.8
10 years 2.35
Extreme 2.35
28.5
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
12/9/25 A Buy

Director

15,000 0.0095%
12/9/25 A Sell

Director

15,000 0.0095%
11/28/25 A Buy

Director

15,900 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
+7.64%-4.93%-58.59%-64.56% 41.13M
-0.31%-1.94%-24.39%+2.91% 175B
+0.97%-2.45%-5.01%+13.74% 114B
-1.01%-4.01%-1.04%+66.14% 57.98B
+0.01%+1.73%-0.42%-30.03% 50.07B
-1.79%-0.54%+13.21%+50.18% 50.13B
+0.07%-2.79%+29.18%-9.20% 32.71B
+1.07%+9.73% - - 30.77B
+1.41%+3.83%+43.64%-0.90% 26.44B
+1.98%+7.44%+26.26%-1.90% 23.96B
Average +0.99%+0.94%+2.54%+2.93% 56.13B
Weighted average by Cap. +0.04%-0.18%-2.86%+12.36%

Financials

2026 *2027 *
Net sales 128M 12.82M 11.28M 10.67M 9.67M 18.17M 1.23B 18.27M 49.32M 628M 48.15M 47.1M 2.02B 204M 20.49M 18.02M 17.04M 15.45M 29.02M 1.97B 29.19M 78.79M 1B 76.91M 75.25M 3.22B
Net income -68.9M -6.92M -6.09M -5.75M -5.22M -9.8M -664M -9.86M -26.61M -339M -25.98M -25.41M -1.09B -36.8M -3.7M -3.25M -3.07M -2.79M -5.24M -355M -5.27M -14.21M -181M -13.87M -13.57M -582M
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
28/09/26 SEK 2.605 +7.64% 3,293,674
25/09/26 SEK 2.420 -5.65% 1,181,271
24/09/26 SEK 2.565 +0.39% 920,674
23/09/26 SEK 2.555 -4.49% 1,168,788
22/09/26 SEK 2.675 -2.37% 753,216

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SEZI Stock